ClinicalTrials.gg
WithdrawnNCT03499041Updated Jun 28, 2018

A Study of LY3314814 in Participants With Liver Impairment

A Phase 1 interventional study of LY3314814 in Hepatic Impairment, sponsored by Eli Lilly and Company. Withdrawn at 4 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-28.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

How we know

Why this study was withdrawn
Stopped for futility. Phase 3 studies not likely to meet primary endpoints.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of the study is to determine whether LY3314814 can be safely prescribed in participants with liver impairment without a dose adjustment. Participants will be on study for 11 days with follow-up about 7 days afterward.

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) of 18 to 40 kilogram per meter square (kg/m²), inclusive, at the time of screening

Exclusion criteria

Exclusion Criteria:

  • Have a history of or current significant ophthalmic disease, particularly any eye problem involving the retina
  • Have moderate or severe vitiligo or any other disorder of skin or hair pigmentation
  • Have acute unstable neuropsychiatric disease
  • Have active or uncontrolled neurologic disease, or clinically significant head injury
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    LY3314814 Control

    LY3314814 administered orally to participants with normal hepatic function

    Drug: LY3314814

  • Experimental
    LY3314814 Mild

    LY3314814 administered orally to participants with mild hepatic impairment

    Drug: LY3314814

  • Experimental
    LY3314814 Moderate

    LY3314814 administered orally to participants with moderate hepatic impairment

    Drug: LY3314814

  • Experimental
    LY3314814 Severe

    LY3314814 administered orally to participants with severe hepatic impairment

    Drug: LY3314814

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) of LY3314814

    PK: AUC(0-∞) of LY3314814

    Time frame: Baseline through 240 hours after the administration of study drug

  2. PK: Maximum Observed Drug Concentration (Cmax) of LY3314814

    PK: Cmax of LY3314814

    Time frame: Baseline through 240 hours after the administration of study drug

07

Study locations

4 sites
  • Orange County Research Center
    Tustin, California 92780, United States
  • Clinical Pharmacology of Miami
    Miami, Florida 33014, United States
  • Orlando Clinical Research Ctr
    Orlando, Florida 32809, United States
  • New Orleans Cntr for Clin Res
    Knoxville, Tennessee 37920, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2018; primary completion for Dec 2018, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2018
First posted
Apr 17, 2018
StartEst.
Jun 2018
Primary completionEst.
Dec 2018
CompletionEst.
Dec 2018
Last update
Jun 28, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03499041
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Apr 17, 2018
Start date
Jun 2018 (estimated)
Primary completion
Dec 2018 (estimated)
Completion
Dec 2018 (estimated)
Last update
Jun 28, 2018

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lanabecestat

Start the discussion